Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared a post on X:
“The Phase III ADAPTela (NCT07242352) trial evaluates whether elacestrant—a next-generation oral SERD— can outperform standard endocrine therapy in intermediate–high-risk HR+/HER2− early Breast Cancer.”
Read more about the clinical trial.
More posts about Breast Cancer.